6IB Stock Chart & Stats
€11.85
-€0.15(-1.51%)
At close: 4:00 PM EDT
€11.85
-€0.15(-1.51%)
Day’s Range― - ―
52-Week Range€7.91 - €12.10
Previous CloseN/A
Volume0.00
Average Volume (3M)32.00
Market Cap
€18.39B
Enterprise Value€122.92B
Total Cash (Recent Filing)€20.00B
Total Debt (Recent Filing)€2.32B
Price to Earnings (P/E)111.4
Beta0.36
Next Earnings
Mar 31, 2027EPS Estimate
0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.71
Shares Outstanding1,746,918,300
10 Day Avg. Volume0
30 Day Avg. Volume32
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)6.12
Price to Sales (P/S)9.09
P/FCF Ratio12.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€15.23Price Target Upside28.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
EPS Forecast (FY)0.15
Revenue Forecast (FY)€2.09B
Bulls Say, Bears Say
Bulls Say
Revenue And Earnings InflectionThe 2025 revenue and earnings inflection indicates that commercial products and operating execution can support a larger business base. If maintained, higher sales and positive earnings should improve internal funding for pipeline development and commercialization over the next several quarters.
Strong Gross MarginsGross margin reached 86.5%, up from 84.0% in 2024 and 70.9% in 2023, showing strong economics in the biologics portfolio. This provides room to absorb research, development, and commercial costs while preserving operating leverage as product sales expand.
Conservative Balance SheetDebt-to-equity fell to about 0.15 from 0.22 in 2024, while equity rose to 19.4B. This stronger capital base reduces balance-sheet strain and gives Innovent greater flexibility to fund clinical programs, manufacturing capacity, and commercialization without relying as heavily on debt.
Bears Say
Unproven Profitability DurabilityDespite 2025 profitability, Innovent recorded operating losses in every year from 2020 through 2024, and returns remained modest. This history suggests the latest improvement has not yet established a durable earnings pattern, leaving execution and sustained commercialization as important risks.
Uneven Historical Cash FlowThe sharp 2025 cash improvement is not yet fully validated by the prior record, which included prolonged negative free cash flow and earlier operating cash burn. If cash conversion normalizes below 2025 levels, Innovent may have less internally generated funding for pipeline investment and expansion.
Low Net Profit ConversionThe wide gap between Innovent’s 86.5% gross margin and 6.2% net margin shows that substantial costs remain after production, limiting current earnings conversion. Sustained research, development, and commercialization expenses could constrain bottom-line leverage as the company grows.
Innovent Biologics News
6IB FAQ
What was Innovent Biologics’s price range in the past 12 months?
Innovent Biologics lowest stock price was €7.91 and its highest was €12.10 in the past 12 months.
What is Innovent Biologics’s market cap?
Innovent Biologics’s market cap is €18.39B.
When is Innovent Biologics’s upcoming earnings report date?
Innovent Biologics’s upcoming earnings report date is Mar 31, 2027 which is in 170 days.
How were Innovent Biologics’s earnings last quarter?
Innovent Biologics released its earnings results on Aug 25, 2026. The company reported €0.092 earnings per share for the quarter, beating the consensus estimate of €0.062 by €0.03.
Is Innovent Biologics overvalued?
According to Wall Street analysts Innovent Biologics’s price is currently Undervalued.
Does Innovent Biologics pay dividends?
Innovent Biologics does not currently pay dividends.
What is Innovent Biologics’s EPS estimate?
Innovent Biologics’s EPS estimate is 0.15.
How many shares outstanding does Innovent Biologics have?
Innovent Biologics has 1,746,918,300 shares outstanding.
What happened to Innovent Biologics’s price movement after its last earnings report?
Innovent Biologics reported an EPS of €0.092 in its last earnings report, beating expectations of €0.062. Following the earnings report the stock price went up 3.906%.
Which hedge fund is a major shareholder of Innovent Biologics?
Currently, no hedge funds are holding shares in DE:6IB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Innovent Biologics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-0.27%
12-Months-Change
Fundamentals
Return on Equity
6.06%
Trailing 12-Months
Asset Growth
86.27%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Innovent Biologics
Innovent Biologics, Inc., established in 2011 and headquartered in Suzhou, People's Republic of China, functions as a leading biopharmaceutical enterprise. The company is dedicated to the comprehensive lifecycle of antibody drug candidates, encompassing their discovery, development, and eventual manufacturing. Its therapeutic focus spans critical areas such as oncology, ophthalmology, immunology, and metabolic diseases. A key product in its portfolio is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody utilized in the treatment of various cancers, including Hodgkin's lymphoma and esophageal carcinoma. Innovent's commercialized offerings also include Byvasda, employed for several malignant tumors; Halpryza, which addresses non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and Wegener's granulomatosis; Pemazyre, indicated for adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib, designed for adult patients facing conditions related to tyrosine kinase inhibitors; and Cyramza, approved for four distinct cancer types. The company's robust pipeline features a range of investigational therapies, such as IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein aimed at ocular fundus disease; IBI-306, a human monoclonal antibody targeting hypercholesterolemia; and IBI-310, a recombinant human anti-CTLA-4 monoclonal antibody for liver and renal cell carcinoma. Further developmental assets include IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for adults with relapsed or refractory multiple myeloma; IBI-376 for recurrent or refractory follicular lymphoma; and IBI-112 for psoriasis. Beyond drug creation, Innovent Biologics is also involved in distributing pharmaceutical products and provides expert consultation along with research and development services. The company maintains key strategic alliances with various partners, including NeoCura Bio-Medical Technology Co. Ltd., Roche Group, Ascentage Pharma Group International, Eli Lilly and Company, and Bolt Biotherapeutics, Inc.
6IB Stock 12 Month Forecast
Average Price Target
€15.23
▲(28.49% Upside)
Technical Analysis
3SBio
―
Akeso, Inc.
―
RemeGen Co. Ltd. Class H
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―